May 05, 2008, 06.46 PM IST | Source:

Glenmark launches topical antifungal cream - Onabet

Glenmark Pharmaceuticals Ltd, one of Indias leading research-led, integrated pharmaceutical companies, launched its topical antifungal cream Onabet (sertaconazole nitrate 2% cream) in the Indian market.

Glenmark Pharmaceuticals Ltd. (GPL), one of Indias leading research-led, integrated pharmaceutical companies, today launched its topical antifungal cream Onabet (sertaconazole nitrate 2% cream) in the Indian market.


Onabet, a benzothiophene imidazole agent has a broad spectrum of coverage against dermatophytes, yeasts including candida, other filamentous fungi and bacteria associated with cutaneous fungal infections.


Cutaneous fungal infections like tinea (commonly known as ringworm) and candidal skin infections affect millions of people across the world.  In some cases complete cure is not achieved due to increasing pathogenicity of many fungal micro-organisms and decreasing sensitivity to traditional antifungal agents. Incomplete treatment of cutaneous fungal infections may further lead to relapse thereby producing significant morbidity.


The fungicidal mechanism in Onabet reduces the chances of relapse by offering better penetration and long term residency within the skin. The substantial anti-inflammatory action further provides rapid symptomatic relief in cases of fungal infections with inflammation and pruritis. The active ingredient in Onabet, sertaconazole nitrate, has been approved by US FDA and is marketed in over 24 countries worldwide.


Glenmark Pharmaceuticals Ltd. has been rendering its services to the medical fraternity and patients of superficial fungal infections through time tested antifungal preparations like Candid and Candid B. With the launch of Onabet, Glenmark further strengthens its antifungal management armamentarium. 


Sourced From: Glenmark Pharmaceuticals Limited

Glenmark stock price

On April 16, 2014, Glenmark Pharma closed at Rs 583.10, up Rs 1.75, or 0.30 percent. The 52-week high of the share was Rs 612.00 and the 52-week low was Rs 467.50.

The company's trailing 12-month (TTM) EPS was at Rs 13.53 per share as per the quarter ended December 2013. The stock's price-to-earnings (P/E) ratio was 43.1. The latest book value of the company is Rs 93.03 per share. At current value, the price-to-book value of the company is 6.27.

Set email alert for


Buy & sell politicians on Power Play
- the political stock exchange

Price Update

Rahul Gandhi

594.76 -2.35 -0.39%


Bought today


Sold today


User holding

video of the day

Ambit Cap eyes two years of market cheer; bets on cyclicals

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.